超声裂解液细胞构成经转录组去卷积预测可区分感染性与非感染性关节置换失败
研究采用CIBERSORTx对93份超声裂解液样本(53份假体周围关节感染导致的关节置换失败,40份非感染性关节置换失败)的批量RNA测序数据进行细胞构成预测,发现基于预测细胞构成的主成分分析可区分两组,预测的中性粒细胞、活化肥大细胞、嗜酸性粒细胞及总粒细胞分数在感染组升高,ROC曲线分析显示预测总粒细胞、中性粒细胞和活化肥大细胞能高度区分两组。
要点
- CIBERSORTx可基于转录组数据预测超声裂解液细胞构成,无需表型评估细胞组成。
- 预测的总粒细胞、中性粒细胞和活化肥大细胞在区分感染性与非感染性关节置换失败上表现高度区分能力。
- 感染组预测中性粒细胞、活化肥大细胞、嗜酸性粒细胞及总粒细胞分数升高,非感染组预测总巨噬细胞和单核细胞及总B细胞分数升高。
核心结论
- CIBERSORTx可利用转录组数据预测超声裂解液的细胞构成,从而在无需对细胞组成进行表型评估的情况下,评估假体周围关节感染导致的关节置换失败与非感染性关节置换失败病例的 underlying 免疫反应。
研究设计与样本
- 研究纳入93份超声裂解液样本,其中53份来自假体周围关节感染导致的关节置换失败受试者(本研究简称为PJIF),40份来自非感染性关节置换失败受试者(简称为NIAF),对所有样本进行批量RNA测序,并采用CIBERSORTx(斯坦福大学)转录组细胞去卷积工具预测细胞构成。
主要发现
- 基于预测细胞构成的主成分分析可将PJIF与NIAF样本区分聚类。
- 22个预测细胞组分中有12个在PJIF与NIAF病例间差异表达,包括预测中性粒细胞(均值±标准误:9.73%±1.06% vs 0.81%±0.60%)、活化肥大细胞(17.12%±1.51% vs 4.11%±0.44%)和嗜酸性粒细胞(1.96%±0.37% vs 0.42%±0.21%)在PJIF升高,以及预测M0巨噬细胞(21.33%±1.51% vs 39.75%±2.45%)、M2巨噬细胞(3.56%±0.52% vs 8.70%±1.08%)和调节性T细胞(1.57%±0.23% vs 3.20%±0.34%)在PJIF降低。
- 预测总粒细胞分数在PJIF病例升高(32.97%±2.13% vs 11.76%±1.61%),NIAF病例的预测总巨噬细胞和单核细胞分数(34.71%±1.71% vs 55.34%±2.37%)及总B细胞分数(5.89%±0.30% vs 8.62%±0.86%)升高。
- 受试者工作特征曲线分析确定预测总粒细胞、中性粒细胞和活化肥大细胞能高度区分PJIF与NIAF病例。
- 在PJIF病例内,预测总粒细胞、总巨噬细胞和单核细胞、M0巨噬细胞及M2巨噬细胞分数在金黄色葡萄球菌相关样本与表皮葡萄球菌相关样本间差异表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although cellularity is traditionally assessed morphologically, deep sequencing approaches being used for microorganism detection may be able to provide information about cellularity. We hypothesized that cellularity predicted using CIBERSORTx (Stanford University), a transcriptomic-based cellular deconvolution tool, would differentiate between infectious and non-infectious arthroplasty failure. METHODS: CIBERSORTx-derived cellularity profiles of 93 sonicate fluid samples, including 53 from subjects who underwent failed arthroplasties due to periprosthetic joint infection (PJI) (abbreviated for the purpose of this study as PJIF) and 40 from subjects who had undergone non-infectious arthroplasty failure (abbreviated NIAF) that had been subjected to bulk RNA sequencing were evaluated. RESULTS: Samples from PJIF and NIAF subjects were differentially clustered by principal component analysis based on the cellularity profile. Twelve of the 22 individual predicted cellular fractions were differentially expressed in the PJIF cases compared with the NIAF cases, including increased predicted neutrophils (mean and standard error, 9.73% ± 1.06% and 0.81% ± 0.60%), activated mast cells (17.12% ± 1.51% and 4.11% ± 0.44%), and eosinophils (1.96% ± 0.37% and 0.42% ± 0.21%), and decreased predicted M0 macrophages (21.33% ± 1.51% and 39.75% ± 2.45%), M2 macrophages (3.56% ± 0.52% and 8.70% ± 1.08%), and regulatory T cells (1.57% ± 0.23% and 3.20% ± 0.34%). The predicted total granulocyte fraction was elevated in the PJIF cases (32.97% ± 2.13% and 11.76% ± 1.61%), and the samples from the NIAF cases had elevated predicted total macrophage and monocyte (34.71% ± 1.71% and 55.34% ± 2.37%) and total B cell fractions (5.89% ± 0.30% and 8.62% ± 0.86%). Receiver operating characteristic curve analysis identified predicted total granulocytes, neutrophils, and activated mast cells as highly able to differentiate between the PJIF cases and the NIAF cases. Within the PJIF cases, the total granulocyte, total macrophage and monocyte, M0 macrophage, and M2 macrophage fractions were differentially expressed in Staphylococcus aureus compared with Staphylococcus epidermidis -associated samples. Within the NIAF cases, the predicted total B cell, naïve B cell, plasma cell, and M2 macrophage fractions were differentially expressed among different causes of failure. CONCLUSIONS: CIBERSORTx can predict the cellularity of sonicate fluid using transcriptomic data, allowing for the evaluation of the underlying immune response during the PJIF and NIAF cases, without a need to phenotypically assess cell composition.
引用
- Fisher CR, Krull JE, Bhagwate A, et al. Sonicate Fluid Cellularity Predicted by Transcriptomic Deconvolution Differentiates Infectious from Non-Infectious Arthroplasty Failure. J Bone Joint Surg Am. 2022. PMID: 36574631. doi:10.2106/JBJS.22.00605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。